Clinical trials · California
Leukemia clinical trials in California
We’re tracking 177 recruiting leukemia studies with a site in California — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT00186147Enrolling by invitation
Bone marrow grafting for leukemia and lymphoma
This study involves bone marrow cell grafting for people affected by leukemia or lymphoma. You may be eligible if you are a transplant recipient or a donor and you freely choose to take part.
Stanford, CaliforniaAges 18–70 - NCT07400029RecruitingPhase 2
Obecabtagene autoleucel for B-cell ALL in remission
This trial tests a new cell therapy called obecabtagene autoleucel (a 'living drug' made from your own immune cells) for people with a type of blood cancer (B-cell ALL) that has responded to initial treatment but may still have tiny traces. The goal is to see if it can prevent relapse after remission.
Duarte, CaliforniaAges 40 years+ - NCT04836390Enrolling by invitationPhase 2
Donor immune cell treatment after transplant for high-risk AML
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
Los Angeles, CaliforniaAges birth–25 years - NCT05188170RecruitingPhase 1
Niclosamide for children and young adults with difficult leukemia
This Phase 1 study tests niclosamide, a medicine being studied as a new treatment, for pediatric and young adult AML that has come back or did not respond. It mainly focuses on whether the drug can be given safely and what dose might work best.
Palo Alto, CaliforniaAges 2–25 - NCT05621291Recruiting
Sequencing test to guide care after CD19 CAR T in kids
This study checks a DNA-based lab test (next-generation sequencing, or NGS) to monitor B-cell recovery after CD19 CAR T treatment in children and young adults. The goal is to see whether the test can help guide management while looking for remission and safe recovery.
Los Angeles, CaliforniaAges 1–25 - NCT06943872RecruitingPhase 3
Comparing new treatments for relapsed CLL or SLL
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
Laguna Hills, CaliforniaAges 18 years+ - NCT05006716RecruitingPhase 1/Phase 2
Testing a new drug for certain B-cell blood cancers
This Phase 1/2 trial studies the safest dose and then effectiveness of BGB-16673 in people with specific B-cell malignancies. It may help by targeting cancer cells in these blood cancers, especially after other treatments like BTK inhibitors.
La Jolla, CaliforniaAges 18 years+ - NCT06366789RecruitingPhase 1
Testing a new drug for AML with FLT3 or spliceosome mutations
This trial tests a new drug called ZE46-0134 for adults with AML that has a specific gene change (FLT3 or spliceosome mutation) and hasn't been controlled by prior treatment. It aims to find the right dose and see if it can help stop the leukemia from growing.
Los Angeles, CaliforniaAges 18 years+ - NCT07573111RecruitingPhase 1
QUAIL-100 for Children With Blood Cancers After Stem Cell Transplant
This study tests a new experimental treatment called QUAIL-100 in children and young adults who have had a stem cell transplant for a serious blood cancer. The treatment is designed to help the immune system fight remaining cancer cells.
Palo Alto, CaliforniaAges 1.5 years–39 years - NCT07221500RecruitingPhase 2
Study of NX-5948 for advanced CLL or SLL
This trial tests an experimental drug called NX-5948 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments. It's for those who have already tried a BTK inhibitor and a BCL-2 inhibitor.
Duarte, CaliforniaAges 18 years+ - NCT05554393RecruitingPhase 2
Treating intermediate-risk AML in younger adults
This trial compares three different drug combinations for younger adults (18-59) with intermediate-risk AML. You will be assigned to one of three groups: standard chemotherapy (cytarabine + daunorubicin), that same chemotherapy plus venetoclax, or venetoclax combined with azacitidine.
Berkeley, CaliforniaAges 18–59 - NCT06652438RecruitingPhase 3
Revumenib plus standard drugs for NPM1 or KMT2A AML
This trial tests adding a new targeted drug, revumenib, to two standard AML medicines (azacitidine and venetoclax) for adults with a specific gene change (NPM1 mutation or KMT2A rearrangement) who cannot receive strong chemotherapy. The goal is to see if the combination works better.
Los Angeles, CaliforniaAges 18 years+ - NCT07424833RecruitingPhase 1
Study of APG-3288 for Relapsed/Refractory Blood Cancers
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Los Angeles, CaliforniaAges 18 years+ - NCT07007312RecruitingPhase 3
Ziftomenib plus standard chemo for certain AML patients
This trial tests a new drug, ziftomenib, added to standard chemotherapy for adults with untreated acute myeloid leukemia (AML) who have specific gene changes (NPM1 mutation or KMT2A rearrangement). It aims to see if the combination works better than standard treatment alone.
Clovis, CaliforniaAges 18 years+ - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Los Angeles, CaliforniaAges 6 months–25 years - NCT04227847RecruitingPhase 1
Study of a CD70-targeting drug for blood cancer
This Phase 1 study tests the safety of SEA-CD70, a drug that targets CD70, in people with certain blood cancers like MDS and AML. It may help doctors learn whether this approach can be used safely for patients whose disease has come back or not responded to standard treatments.
Duarte, CaliforniaAges 18 years+ - NCT07250646RecruitingPhase 1
Rebecsinib for secondary AML or high-risk myelofibrosis
This trial tests a new drug called rebecsinib for people with a certain type of leukemia (secondary acute myeloid leukemia) or a high-risk bone marrow disorder (myelofibrosis) that has come back or not responded to other treatments. The goal is to see if it works and is safe.
Duarte, CaliforniaAges 18 years+ - NCT05429632RecruitingPhase 3
Mocravimod to prevent relapse after bone marrow transplant for AML
This Phase 3 trial tests mocravimod, added to standard care, to help keep acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow (stem cell) transplant. It may help by supporting long-term remission during the transplant recovery period.
Duarte, CaliforniaAges 18–75 - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Duarte, CaliforniaAges Any age - NCT03509961RecruitingPhase 2
Reducing total body radiation for children with leukemia transplants
This study looks at whether some children and young adults with B-ALL can safely get a transplant without total body irradiation (TBI), based on special leukemia test results. It’s meant to help lower radiation-related risks while keeping leukemia control strong.
San Francisco, CaliforniaAges 1–25 - NCT03568266Recruiting
Genetic study of liver injury from a leukemia medicine
This study looks at why some people develop liver problems while taking asparaginase, a common medicine used to treat newly diagnosed acute lymphoblastic leukemia (ALL). The goal is to use genetic information to better understand and potentially prevent this side effect.
Los Angeles, CaliforniaAges 18 years+ - NCT03719105RecruitingEarly Phase 1
Chemo plus immunotherapy with donor stem cell transplant for NK lymphoma
This early-phase study tests a combination treatment—chemo, immunotherapy, and a donor stem cell transplant—for certain aggressive NK/T-cell lymphomas. It may help patients who have advanced-stage disease by trying to improve long-term control of the cancer.
Orange, CaliforniaAges 1–31 - NCT03728335RecruitingPhase 2
Enasidenib maintenance after transplant for IDH2-mutated AML
This trial studies enasidenib to help keep acute myeloid leukemia (AML) under control after an allogeneic stem cell transplant in people with an IDH2 mutation. It may help reduce the chance of the leukemia coming back by targeting the mutation that drives the disease.
Duarte, CaliforniaAges 18 years+ - NCT03801434RecruitingPhase 2
Ruxolitinib for people with certain eosinophil overgrowth diseases
This trial studies ruxolitinib to treat illnesses where the body makes too many eosinophils (a type of white blood cell) and symptoms or organ damage happen. It may help shrink disease activity when steroids are not enough, cannot be tolerated, or the illness comes back.
Palo Alto, CaliforniaAges 18 years+
Leukemia trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting leukemia studies listed above.
- City of Hope Comprehensive Cancer Center · 6 studies
- University of California, Los Angeles (UCLA) · 5 studies
- Children's Hospital Los Angeles · 4 studies
- Stanford University · 4 studies
- Cedars-Sinai Medical Center · 3 studies
- University of California, San Francisco · 3 studies
- UCSF · 2 studies
- University of California San Diego Health · 2 studies
What taking part in a leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Leukemia trials in other states
Common questions
- Are there leukemia clinical trials in California?
- Yes. We're currently tracking 177 recruiting leukemia studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a leukemia study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New leukemia studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.